Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

Texas MPN Workshop 2022 | Upcoming agents in ET and PV

Ruben Mesa • 26 Aug 2022
Texas MPN Workshop 2022
Essential Thrombocythemia Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases Bomedemstat Ropeginterferon alfa-2b Rusfertide

Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, gives an overview of upcoming agents in polycythemia vera (PV) and essential thrombocythemia (ET), including ropeginterferon alfa-2b, bomedemstat, and rusfertide, and clinical trials investigating these agents. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

More from Ruben Mesa

Time without transfusion reliance: quantifying transfusion independence in myelofibrosis 3:11
Time without transfusion reliance: quantifying transfusion independence in myelofibrosis
Ruben Mesa • 23 Aug 2025
The recent shortage of peginterferon alfa-2a and the role of this agent in MPNs 2:12
The recent shortage of peginterferon alfa-2a and the role of this agent in MPNs
Ruben Mesa • 23 Aug 2025
The value and interactive format of the MPN Workshop of the Carolinas 6:05
The value and interactive format of the MPN Workshop of the Carolinas
Naveen Pemmaraju et al. • 22 Aug 2025
The role of non-pharmacological interventions in reducing the symptom burden in MPNs 1:39
The role of non-pharmacological interventions in reducing the symptom burden in MPNs
Ruben Mesa • 23 Aug 2025

Related Videos

Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach 2:14
Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach
John Mascarenhas • 4 Sep 2025
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors 1:19
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors
John Mascarenhas • 3 Sep 2025
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS 10:06
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS
Asfand Yar Cheema • 5 Sep 2025
The value of fedratinib for the treatment of patients with MF in the second-line setting 1:19
The value of fedratinib for the treatment of patients with MF in the second-line setting
Francesco Passamonti • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals